JP2009541373A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541373A5
JP2009541373A5 JP2009516901A JP2009516901A JP2009541373A5 JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5 JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5
Authority
JP
Japan
Prior art keywords
vaccine
adjuvant
peptide
protein
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009516901A
Other languages
English (en)
Japanese (ja)
Other versions
JP5165681B2 (ja
JP2009541373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2007/000312 external-priority patent/WO2008000261A2/en
Publication of JP2009541373A publication Critical patent/JP2009541373A/ja
Publication of JP2009541373A5 publication Critical patent/JP2009541373A5/ja
Application granted granted Critical
Publication of JP5165681B2 publication Critical patent/JP5165681B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009516901A 2006-06-28 2007-06-26 タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大 Expired - Fee Related JP5165681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600861 2006-06-28
DKPA200600861 2006-06-28
PCT/DK2007/000312 WO2008000261A2 (en) 2006-06-28 2007-06-26 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Publications (3)

Publication Number Publication Date
JP2009541373A JP2009541373A (ja) 2009-11-26
JP2009541373A5 true JP2009541373A5 (enExample) 2010-07-29
JP5165681B2 JP5165681B2 (ja) 2013-03-21

Family

ID=38845996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516901A Expired - Fee Related JP5165681B2 (ja) 2006-06-28 2007-06-26 タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大

Country Status (11)

Country Link
US (2) US8105614B2 (enExample)
EP (3) EP2040745B1 (enExample)
JP (1) JP5165681B2 (enExample)
KR (1) KR20090024292A (enExample)
AU (1) AU2007264205B2 (enExample)
BR (1) BRPI0713978A2 (enExample)
CA (1) CA2654271A1 (enExample)
DK (1) DK2040745T3 (enExample)
ES (1) ES2400531T3 (enExample)
RU (1) RU2490024C2 (enExample)
WO (1) WO2008000261A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6480999A (en) 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2008145129A2 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
PL2167124T3 (pl) * 2007-06-29 2012-12-31 Statens Seruminstitut Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
HUE030520T2 (en) * 2008-11-28 2017-05-29 Statens Seruminstitut Optimized influenza vaccines
KR20170072366A (ko) * 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
CA2769996C (en) * 2009-11-05 2018-06-12 The United States Of America As Represented By The Secretary Of The Na Plasmodium falciparum sporozoite and liver stage antigens
WO2011063133A1 (en) * 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
DK3079716T3 (da) * 2013-12-13 2019-08-19 Us Health Multiepitop-tarp-peptidvaccine og anvendelser deraf.
BR112016023778A2 (pt) 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
CN117064854A (zh) * 2023-08-14 2023-11-17 广州谦毅生物医药有限公司 一种卡瓦脂质体的制备技术

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
PT992580E (pt) * 1993-11-04 2005-07-29 Innogenetics Nv Epitopos para celulas t humanas imunodominantes do virus da hepatite c
KR100797876B1 (ko) * 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
SE9903031D0 (sv) 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AU2003245729A1 (en) * 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
ATE406874T1 (de) 2004-07-07 2008-09-15 Statens Seruminstitut Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
FR2873467A1 (fr) 2004-07-26 2006-01-27 Proton World Internatinal Nv Enregistrement d'une cle dans un circuit integre
ES2425576T3 (es) * 2006-01-26 2013-10-16 Zoetis P Llc Composiciones coadyuvantes glucolipídicas novedosas
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides

Similar Documents

Publication Publication Date Title
Kaur et al. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects
US12070498B2 (en) Conjugate vaccine targeting a disease-causing biological protein
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
CN103747797B (zh) 脂质体制剂
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
EP2200638B1 (en) Compositions for the transfection of cells
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
JP2011512123A5 (enExample)
RU2009102389A (ru) Расширение спектра клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
JP2011518179A5 (enExample)
JP5766894B2 (ja) ワクチン増強剤としてのαチモシンペプチド
JP2014509594A (ja) 炎症を抑制するためのペプチド
CN102088992B (zh) 肽基二酰基甘油酯
Yan et al. Recent Advances in Liposome‐Based Nanoparticles for Antigen Delivery
JP5481762B2 (ja) 脳移行性機能性核酸及びその利用
JP7050807B2 (ja) 新規ペプチドベースのｐｃｓｋ９ワクチン
CN119818665A (zh) 新型发热伴血小板减少综合征病毒疫苗
JP2008531463A5 (enExample)
KR20090009839A (ko) 면역조절 올리고펩티드
CN101336110B (zh) 预防或治疗肝损伤的肽及其衍生物及其应用
RU2003110420A (ru) Дифференцирование gnrh-i и gnrh-ii
RU2377249C2 (ru) Биологически активные производные пептида vapeehptllteaplnpk
CN102178926A (zh) 预防或治疗肝损伤的肽
OA21833A (en) Immunogenic fusion protein.